Goldman Sachs Quietly Shapes ABA Landscape with CSD-BCI Deal

The Quiet Deal That Matters

ALBUQUERQUE, NEW MEXICO — While industry attention in early 2026 stayed fixed on platform-level transactions and sponsor-to-sponsor transfers, the Center for Social Dynamics completed something smaller and more instructive: a tuck-in acquisition of the Behavior Change Institute, a New Mexico-based autism services provider founded in 2014.

The deal closed February 19. Financial terms were not disclosed. BCI will operate as part of CSD rather than as a distinct brand, with integration proceeding in phases over the next 12 to 18 months. By the time it is complete, CSD expects to have folded BCI’s clinical data, academic partnerships, and rural telehealth infrastructure into a shared platform it has been building since Goldman Sachs Alternatives completed its acquisition of CSD from NMS Capital in December 2024.

This is the first acquisition CSD has made under Goldman Sachs ownership. That timing matters. Goldman paid an undisclosed sum for CSD from NMS, which reinvested alongside the new backer. The fund acquired a company that had already done five tuck-ins between 2020 and 2021 and had since spent several years focused on internal operations: scheduling, professional development, and the buildout of a digital ABA platform. The BCI deal signals that acquisition mode is back on, and the target profile is telling.

The pipeline in ABA is heavy on giant deals. Tuck-ins like this one are where the consolidation thesis is actually playing out quarter by quarter.

BCI is not a large operator by national standards. It has offices in southern and northern New Mexico and in western Texas. What it has built over 12 years, however, is harder to replicate than clinic square footage: a PhD-level clinical research infrastructure, academic collaborations, a track record in rural telehealth delivery, and deep credibility in a market with significant Medicaid complexity and cultural nuance.

How BCI Was Built

The Behavior Change Institute was founded in 2014 by Dr. Joy Pollard and Kathleen Karimi. The origin story is specific and it matters for understanding why CSD wanted this organization.

Dr. Pollard holds a PhD in Disability Disciplines with a specialization in applied behavior analysis from Utah State University. When her nephew was diagnosed with autism and the family, living in rural New Mexico, could not access medically necessary treatment, Pollard began developing solutions. She and Karimi co-founded BCI specifically to provide services in rural and underserved communities, starting in Alamogordo before expanding across the state.

Pollard’s academic work has been active throughout BCI’s operational history. She holds an adjunct lectureship at Stanford University and serves as co-investigator on research projects focused on telehealth delivery of ABA interventions. She has supervised multistate telehealth services since 2011. She served as President of the New Mexico Association for Behavior Analysis and co-chairs the state’s Public Policy Committee.

Karimi’s background: Kathleen Karimi earned a Master’s in Healthcare Administration from Ohio University and has over 13 years of experience in behavioral health administration, client advocacy, and business development. She has consulted for dozens of provider organizations nationally on telehealth infrastructure, public policy, and quality assurance. At BCI she served as Co-Founder and CEO of Business Operations.

The result of a decade of work by these two founders is a provider with clinical credibility that runs deeper than most tuck-in targets. BCI is known for diagnostic evaluations, early intervention, and evidence-based behavioral therapies. Its strong focus on culturally responsive care, early identification, and access in rural communities built a reputation as one of New Mexico’s most trusted autism providers.

“We founded BCI to close gaps in access, elevate the standard of care, and ensure families receive care that is both compassionate and scientifically grounded. Joining CSD allows us to extend that mission nationally while preserving what makes our clinical culture special.” — Kathleen Karimi, Co-Founder and CEO, Behavior Change Institute (2026)

New Mexico’s ABA Landscape

New Mexico is not where most PE-backed ABA platforms have concentrated their energy. The state’s relatively small population, its large rural and frontier geography, and its high proportion of Medicaid-dependent families have made it less attractive to operators optimizing for commercial payer mix and urban clinic density.

The regulatory environment, however, is coherent. The New Mexico Autism Insurance Act, enacted in 2019, requires insurers to cover the diagnosis and treatment of autism spectrum disorder, including ABA therapy. The state’s Medicaid program, Centennial Care, covers ABA services under its Core Benefits package. Coverage extends to individuals under age 21. In some interpretations, coverage mandates reach to age 23. New Mexico also allows early intervention services for children under three through Medicaid before a formal autism diagnosis is confirmed, which supports earlier access and shorter paths to treatment.

Despite these mandates, access remains uneven. The state ranks among the top in the U.S. for geographic barriers to healthcare, with large portions of the population living more than an hour from a specialist. Rural communities, including many tribal and border communities, face provider shortages that insurance mandates alone cannot resolve. Waitlists are common at most established providers.

BCI’s geographic approach: BCI built its practice specifically around these constraints. Southern New Mexico, where BCI operates out of Alamogordo, is a low-density market far from the Albuquerque metro. Its service model combines in-person delivery with telehealth to reach families that clinic-based providers cannot serve. The company also built operations in western Texas and, at various points, in Alaska and Hawaii, reflecting a deliberate focus on frontier and rural service gaps.

That combination of regulatory clarity, coverage mandates, and genuine access scarcity is a market structure that CSD and Goldman Sachs have reason to value. Markets where demand exceeds supply, payers are required to cover services, and competition is limited by the difficulty of operating in rural geographies rather than by price competition tend to support durable margins for providers who can actually solve the access problem.

What CSD Gets Besides Geography

The geographic argument for this deal is straightforward. CSD, before the BCI acquisition, operated across California, Washington, Oregon, Hawaii, and Colorado, with its virtual CSD Global Community program available nationally. New Mexico and western Texas represent a new footprint in the Southwest.

The more durable rationale is clinical. BCI brings academic research collaborations that CSD describes as deepening expertise across the combined entity and lending themselves well to scale. Dr. Pollard’s role post-acquisition is not an operational one: she will shift her full-time focus to research oversight, developing a pipeline that prioritizes large-scale retrospective outcome studies and prospective research. CSD’s head of integration, Lesley Raskin, described this work as moving beyond internal reporting toward external validation, positioning the combined entity to shape best practices across the field.

That is a different acquisition logic than geography. CSD is not just buying patient volume in New Mexico. It is buying credibility infrastructure: a clinical research lead with Stanford affiliations, a track record in peer-reviewed telehealth research, and a body of clinical data from a population the rest of the industry has largely not served.

The data asset: Raskin described the initial integration priority as consolidating clinical data from thousands of individuals served across CSD and BCI into a shared dataset. The stated goal is rigorous evaluation and testing of which approaches lead to the strongest outcomes, with the intent to build research-ready infrastructure that can support prospective studies. For Goldman Sachs, which has built a reputation in impact investing and outcomes-based thesis development, this research orientation is consistent with the investment rationale.

Families currently served by BCI will keep their existing clinical teams and gain access to CSD’s broader service offerings, immersive learning tools, and enhanced caregiver support. BCI staff will access CSD’s internal training and professional development programs, including a benefit that fully funds college degrees in roles related to employees’ positions. That benefit is unusual in ABA and may be a meaningful retention tool in a market where clinician turnover is a persistent operational risk.

The Goldman Sachs Platform Thesis

CSD under NMS Capital was an acquisitive operator. Between 2020 and 2021, it completed five acquisitions: Rocky Mountain Applied Behavior Analysts, Behavior and Development Center, Ed Support Services, JF Behavioral Services, and South Sound Behavior Therapy. After that run, the focus shifted inward. The years between the acquisition spree and the Goldman Sachs deal in December 2024 were spent on scheduling improvements, professional development expansion, and the build-out of CSD Global Community.

CSD Global Community is the piece of this company that most distinguishes it from other ABA platforms at scale. It is a fully virtual ABA program built on a proprietary clinical curriculum, gamification, and virtual reality tools. CSD partnered with Floreo, a VR startup that in 2023 received FDA breakthrough device designation for its autism technology, to expand VR-enabled curriculum delivery in schools. The program has delivered over 965,000 hours of telehealth ABA and reports 95 percent parent satisfaction, with cancellations reduced by approximately 50 percent compared to in-person sessions.

Goldman Sachs Alternatives managing director Jason Slocum called out the omnichannel delivery model as a specific differentiator at the time of the acquisition. The ability to serve families in whatever setting provides the clinically appropriate number of hours, whether in-home, in centers, in schools, or fully virtually, is what Goldman was buying when it bought CSD. BCI’s rural telehealth infrastructure fits that model.

Goldman Sachs acquired a company with a proven virtual delivery platform, then made its first tuck-in in a rural state where that platform is the most practical way to reach families. The sequence is not coincidental.

The integration timeline of 12 to 18 months is longer than typical tuck-in horizons, but consistent with the complexity involved. BCI brings clinical culture, academic relationships, and a data set that will degrade in value if handled carelessly. Phased integration that preserves BCI’s clinical identity while migrating operations onto CSD’s platform infrastructure is the right approach for this type of target, and the stated commitment to retaining all BCI staff supports that goal.

Kelly Bozarth, CEO of CSD, described the deal as “far more than a geographic expansion,” framing it as a “values-driven union built around impact.” That language is partly a press release, but the structure of the deal supports it. If the research pipeline Dr. Pollard is developing produces publishable outcomes data at scale, it becomes an asset that affects CSD’s credibility with payers, regulators, and future acquirors in ways that another clinic in Albuquerque would not.

What This Deal Signals About 2026

The headline M&A activity in behavioral health in early 2026 has been dominated by sponsor-to-sponsor platform transfers and the handful of large transactions that generate most of the press coverage. What that narrative misses is where deal volume is actually concentrated: regional tuck-ins, bolt-ons for existing platforms, and minority recapitalizations of smaller operators.

A March 2026 industry observer report noted that visible acquisition activity at the platform level remained limited while a fast-growing mid-tier cohort was beginning to pursue selective acquisitions alongside organic growth. The consolidation thesis in ABA has always been about fragmentation: the top ten players account for only 10 to 15 percent of market share, and the remaining 85 to 90 percent is held by providers too small to operate at scale. Tuck-ins are how that math changes, one deal at a time.

The CSD-BCI transaction illustrates something specific about the current phase. The targets drawing the most interest are not just geography. They are capability acquisitions, organizations that bring research infrastructure, rural delivery competence, cultural credibility in specific populations, or clinical data that larger platforms need to substantiate outcomes claims to increasingly skeptical payers and regulators.

The compliance context: Tuck-in risk profiles have shifted. Acquirors in 2026 are not just evaluating EBITDA and clinic counts. The governance environment has tightened following OIG audit findings and increased scrutiny of PE-backed ABA providers. A tuck-in now inherits the target’s documentation practices, compliance posture, and billing history. BCI’s research orientation and mission-driven operating culture, built by founders who prioritized access over scale, represent lower compliance risk than an operator that grew quickly under fee-volume pressure.

The deal also reflects a pattern in how Goldman Sachs thinks about healthcare investments. The firm’s approach through its Alternatives platform emphasizes measurable outcomes and impact investing alongside financial returns. A provider with published research credentials, telehealth scalability, and a demonstrable record of serving Medicaid-dependent rural populations fits that framework in ways that a straightforward clinic roll-up does not.

For the broader ABA industry, the signal from this transaction is worth tracking. When one of the most sophisticated capital allocators in the market makes its first acquisition a rural telehealth operator with a PhD researcher as co-founder and a standing commitment to retrospective outcome studies, it is communicating something about where clinical credibility is heading in terms of value. Operators who have invested in research infrastructure, outcomes measurement, and genuine access in hard-to-serve markets may find themselves positioned as acquisition targets on terms that pure-volume operators cannot match.

SOURCES & REFERENCES